Prognostic implications of stress Tc-99m tetrofosmin myocardial perfusion imaging in patients with left ventricular hypertrophy

The Association Between Left Ventricular Hypertrophy and the Occurrence and Prognosis of Atrial Fibrillation: A Meta-Analysis

Aims: The aim of this study was to perform a meta-analysis of studies of the association of left ventricular hypertrophy (LVH) and atrial fibrillation (AF), especially the predictive and prognostic role of LVH.

Methods and Results: We searched Medline, Embase, and the Cochrane Library from inception through 10 April 2020. A total of 16 cohorts (133,091 individuals) were included. Compared with the normal subjects, patients with LVH were more susceptible to AF (RR = 1.46, 95% CI, 1.32–1.60). In patients with AF and LVH, there was a higher risk of all-cause mortality during 3.95 years (RR = 1.60, 95% CI, 1.42–1.79), and these patients were more likely to progress to persistent or paroxysmal AF (RR = 1.45, 95% CI, 1.20–1.76) than were patients without LVH. After catheter ablation of AF, patients with LVH were more likely to recur (RR = 1.58, 95% CI, 1.27–1.95).

Conclusion: LVH is strongly associated with AF and has a negative impact on outcome in patients with AF.

Treadmill exercise echocardiography as a predictor of events in patients with left ventricular hypertrophy

BACKGROUND

Exercise echocardiography (EE) is recommended for patients with known/suspected coronary artery disease (CAD) and electrocardiogram (ECG) abnormalities. Left ventricular hypertrophy (LVH) is associated with worse outcome and patients with LVH have frequently resting ECG abnormalities. We sought to assess the value of EE for predicting outcome in patients with known/suspected CAD and LVH.

METHODS

Retrospective analysis over 1,058 patients, classified according to the presence (n = 557) or absence (n = 501) of LVH (LV mass > or =163 g for women, > or =225 g for men) who underwent EE. Wall motion score index (WMSI) was evaluated at rest and with exercise. Ischemia was defined as the development of new or worsening wall motion abnormalities (WMA) with exercise. The endpoints were all-cause mortality and major cardiac events (MACE). Overall, 352 patients (33%) developed new/worsening WMA.

RESULTS

During a follow-up of 4.6 +/- 4.0 years, 178 patients died and 129 had a MACE. The 5-year mortality and MACE rates were 6.4 and 7.1% in patients without ischemia vs. 15.3 and 13.6% in those with ischemia, respectively (P < 0.001). In the multivariable analysis, LV mass (hazard ratio (HR) 1.03, 95% confidence interval (CI) 1.02-1.04, P = 0.008) and DeltaWMSI (HR 1.94, 95% CI 1.12-3.35, P = 0.02) were independent predictors of mortality. DeltaWMSI was also an independent predictor of MACE in the overall population (P = 0.002) and in patients with LVH (P = 0.04).

CONCLUSION

LV mass independently predicts mortality, even when EE data are considered. EE provides significant information for predicting events in patients with LVH and known/suspected CAD.